FDA Lymerix Adverse Event Study Set For 2002; Survey To Be Finished By Dec.
Executive Summary
FDA's Center for Biologics Evaluation & Research plans to begin a case control study of GlaxoSmithKline's Lymerix in 2002, following the completion of its survey of Lymerix vaccinees.
You may also be interested in...
GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
FDA Lymerix Study To Test Potential Genetic Marker For Adverse Events
GlaxoSmithKline's Lymerix will be the subject of an FDA case-control study investigating a potential genetic marker for adverse reactions to the Lyme disease vaccine.